Abstract
Purpose :
Lowering intraocular pressure (IOP) is a known effective treatment for glaucoma, there are still many challenges with IOP-lowering drugs in terms of efficacy, duration of action, and patient compliance. We designed Zinc/Iron Mixed-Metal MOF-74 to load the nitric oxide analog Latanoprostene Bunod (LBN), a prostaglandin F2α analog to explore a safe and effective nano-material for delivering LBN with sustained release.
Methods :
This study is based on the advantages of the high drug-loading capacity of Metal-Organic Frameworks (MOFs) using bimetallic MOFs, specifically zinc-iron bimetallic MOFs. Hyaluronic acid (HA) is used as an outer coating to increase biocompatibility. This research employs various methods including molecular, infrared, and electron microscopy to deeply explore the characterization, biocompatibility, and release patterns of the nano-material. The DBA/2 mice, characterized as spontaneous high IOP, were used to investigate the IOP-lowering effects of the nano-material through anterior chamber injection.
Results :
Electron microscopy and the Fourier Transform Infrared Spectroscopy (FTIR) indicated that the LBN was loaded into the C-MOF-75(Zn/Fe), resulting in a novel sustained-release nano-material, namely HA@C-MOF-74(Zn/Fe)@LBN, with a negative zeta potential and a mean particle size of 555 nm. It was found that the nano-material in the range of 0-250 ug/ml showed no cytotoxicity in primary trabecular meshwork cells. DBA/2 mice receiving a single anterior chamber drug delivery show a significant reduction in intraocular pressure, lasting for more than a week.
Conclusions :
The newly developed nano-material represents a promising avenue for reducing intraocular pressure in glaucoma treatment.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.